Reducing cognitive problems caused by radiation therapy for brain cancer
Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction
['FUNDING_SBIR_2'] · IMMUNOCHEM THERAPEUTICS, LLC · NIH-10472755
This study is looking at how to help people with brain cancer who have had radiation therapy by testing a new drug, MW151, that might reduce memory problems and inflammation in the brain, making life a little easier for them during treatment.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | IMMUNOCHEM THERAPEUTICS, LLC (nih funded) |
| Locations | 1 site (NEWTON, UNITED STATES) |
| Trial ID | NIH-10472755 on ClinicalTrials.gov |
What this research studies
This research investigates ways to mitigate cognitive decline and neuroinflammation that often occur after radiation therapy for brain cancer. It focuses on understanding how radiation affects the brain and the role of inflammatory cytokines in causing cognitive impairment. The study aims to evaluate a small molecule drug, MW151, which may help reduce these negative effects and improve cognitive function in patients undergoing treatment. By targeting the inflammatory response, the research seeks to enhance the quality of life for patients who have received radiation therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with brain metastases who are undergoing radiation therapy.
Not a fit: Patients who have not received radiation therapy or those with cognitive impairments unrelated to cancer treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cognitive function and quality of life for patients undergoing radiation therapy for brain cancer.
How similar studies have performed: Other research has shown promise in targeting inflammation to mitigate cognitive decline, suggesting that this approach may be effective.
Where this research is happening
NEWTON, UNITED STATES
- IMMUNOCHEM THERAPEUTICS, LLC — NEWTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHIFRIN, VICTOR — IMMUNOCHEM THERAPEUTICS, LLC
- Study coordinator: SHIFRIN, VICTOR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.